Global Biosimilar Drug

Biosimilar Drug Comprehensive Study by Type (Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others}, Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Others}, Recombinant Peptides {Glucagon, Calcitonin}), Application (Cardiovascular, Rheumatoid Arthrtis, Tumor, Ankylosing Spondylitis, Others), Disease (Oncology Diseases, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Diseases), Form (Tablets, Injection, Others) Players and Region - Global Market Outlook to 2024

Biosimilar Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Biosimilar Drug Market?

Biosimilar pharmaceuticals are drugs that have the same active properties as other licensed drugs. It is believed that biosimilar drugs tend to have a significant impact on the United States as well as the European pharmaceutical industry. Because of increased competition with accelerated biosimilar approvals and their rapid product launch. Increasing usage of biosimilar drugs in various applications such as cardiovascular, rheumatoid arthrtis, tumor, ankylosing spondylitis, among others are likely to be the prime drivers for market growth.

The market study is being classified by Type (Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others}, Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Others} and Recombinant Peptides {Glucagon, Calcitonin}), by Application (Cardiovascular, Rheumatoid Arthrtis, Tumor, Ankylosing Spondylitis and Others) and major geographies with country level break-up.

Pfizer (United States), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen (United States), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), Samsung Biologics (South Korea), Eli Lilly and Company (United States) and Henlius Biotech (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are CP Guojian (China), Novartis International AG (Switzerland), Amgen Inc. (United States), Changchun High Tech (China) and Celgene Corporation (United States).

The biosimilar drug market is highly fragmented with the presence of local and regional players operating in the market. Various players operating in the market such as Pfizer (United States), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen (United States), among others. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Biosimilar Drug market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Biosimilar Drug market by Type, Application and Region.

On the basis of geography, the market of Biosimilar Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Demand for Biosimilar Drugs Due to Their Cost-Effectiveness
  • Rising Incidence of Chronic Diseases across the world

Market Trend
  • Technology Advancement regarding Biosimilar Drug

Restraints
  • Issue related to Innovative Strategies by Biologic Drug Manufacturers

Opportunities
  • New Indications as well as Patent Expiry of Biologic Products
  • Growing Demand from Emerging Economics such as China, India, among others

Challenges
  • Stringent Regulatory Requirements to Adversely Affect Investments in Biosimilars



According to the National Center for Biotechnology Information, “This paper provides an overview of the regulation of biosimilar medicines. Challenges associated with the demonstration of interchangeability and practical considerations relating to switching are also discussed”.

Key Target Audience
Biosimilar Drug Manufacturers, Industry Association, Research and Development (R&D) Companies, Health Insurance Payers, Research Organization, Pharmaceutical and Medical Associations, Federal Agencies and Others

Report Objectives / Segmentation Covered

By Type
  • Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others}
  • Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Others}
  • Recombinant Peptides {Glucagon, Calcitonin}
By Application
  • Cardiovascular
  • Rheumatoid Arthrtis
  • Tumor
  • Ankylosing Spondylitis
  • Others
By Disease
  • Oncology Diseases
  • Chronic Diseases
  • Autoimmune Diseases
  • Blood Disorders
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Other Diseases

By Form
  • Tablets
  • Injection
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand for Biosimilar Drugs Due to Their Cost-Effectiveness
      • 3.2.2. Rising Incidence of Chronic Diseases across the world
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Requirements to Adversely Affect Investments in Biosimilars
    • 3.4. Market Trends
      • 3.4.1. Technology Advancement regarding Biosimilar Drug
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biosimilar Drug, by Type, Application, Disease, Form and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Biosimilar Drug (Value)
      • 5.2.1. Global Biosimilar Drug by: Type (Value)
        • 5.2.1.1. Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others}
        • 5.2.1.2. Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Others}
        • 5.2.1.3. Recombinant Peptides {Glucagon, Calcitonin}
      • 5.2.2. Global Biosimilar Drug by: Application (Value)
        • 5.2.2.1. Cardiovascular
        • 5.2.2.2. Rheumatoid Arthrtis
        • 5.2.2.3. Tumor
        • 5.2.2.4. Ankylosing Spondylitis
        • 5.2.2.5. Others
      • 5.2.3. Global Biosimilar Drug by: Disease (Value)
        • 5.2.3.1. Oncology Diseases
        • 5.2.3.2. Chronic Diseases
        • 5.2.3.3. Autoimmune Diseases
        • 5.2.3.4. Blood Disorders
        • 5.2.3.5. Growth Hormone Deficiency
        • 5.2.3.6. Infectious Diseases
        • 5.2.3.7. Other Diseases
      • 5.2.4. Global Biosimilar Drug by: Form (Value)
        • 5.2.4.1. Tablets
        • 5.2.4.2. Injection
        • 5.2.4.3. Others
      • 5.2.5. Global Biosimilar Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Biosimilar Drug (Volume)
      • 5.3.1. Global Biosimilar Drug by: Type (Volume)
        • 5.3.1.1. Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others}
        • 5.3.1.2. Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Others}
        • 5.3.1.3. Recombinant Peptides {Glucagon, Calcitonin}
      • 5.3.2. Global Biosimilar Drug by: Application (Volume)
        • 5.3.2.1. Cardiovascular
        • 5.3.2.2. Rheumatoid Arthrtis
        • 5.3.2.3. Tumor
        • 5.3.2.4. Ankylosing Spondylitis
        • 5.3.2.5. Others
      • 5.3.3. Global Biosimilar Drug by: Disease (Volume)
        • 5.3.3.1. Oncology Diseases
        • 5.3.3.2. Chronic Diseases
        • 5.3.3.3. Autoimmune Diseases
        • 5.3.3.4. Blood Disorders
        • 5.3.3.5. Growth Hormone Deficiency
        • 5.3.3.6. Infectious Diseases
        • 5.3.3.7. Other Diseases
      • 5.3.4. Global Biosimilar Drug by: Form (Volume)
        • 5.3.4.1. Tablets
        • 5.3.4.2. Injection
        • 5.3.4.3. Others
      • 5.3.5. Global Biosimilar Drug Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Biosimilar Drug (Price)
      • 5.4.1. Global Biosimilar Drug by: Type (Price)
  • 6. Biosimilar Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sandoz International (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceuticals (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Biocon (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dr. Reddy’s Laboratories (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Celltrion (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Samsung Biologics (South Korea)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Henlius Biotech (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Biosimilar Drug Sale, by Type, Application, Disease, Form and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Biosimilar Drug (Value)
      • 7.2.1. Global Biosimilar Drug by: Type (Value)
        • 7.2.1.1. Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others}
        • 7.2.1.2. Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Others}
        • 7.2.1.3. Recombinant Peptides {Glucagon, Calcitonin}
      • 7.2.2. Global Biosimilar Drug by: Application (Value)
        • 7.2.2.1. Cardiovascular
        • 7.2.2.2. Rheumatoid Arthrtis
        • 7.2.2.3. Tumor
        • 7.2.2.4. Ankylosing Spondylitis
        • 7.2.2.5. Others
      • 7.2.3. Global Biosimilar Drug by: Disease (Value)
        • 7.2.3.1. Oncology Diseases
        • 7.2.3.2. Chronic Diseases
        • 7.2.3.3. Autoimmune Diseases
        • 7.2.3.4. Blood Disorders
        • 7.2.3.5. Growth Hormone Deficiency
        • 7.2.3.6. Infectious Diseases
        • 7.2.3.7. Other Diseases
      • 7.2.4. Global Biosimilar Drug by: Form (Value)
        • 7.2.4.1. Tablets
        • 7.2.4.2. Injection
        • 7.2.4.3. Others
      • 7.2.5. Global Biosimilar Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Biosimilar Drug (Volume)
      • 7.3.1. Global Biosimilar Drug by: Type (Volume)
        • 7.3.1.1. Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others}
        • 7.3.1.2. Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Others}
        • 7.3.1.3. Recombinant Peptides {Glucagon, Calcitonin}
      • 7.3.2. Global Biosimilar Drug by: Application (Volume)
        • 7.3.2.1. Cardiovascular
        • 7.3.2.2. Rheumatoid Arthrtis
        • 7.3.2.3. Tumor
        • 7.3.2.4. Ankylosing Spondylitis
        • 7.3.2.5. Others
      • 7.3.3. Global Biosimilar Drug by: Disease (Volume)
        • 7.3.3.1. Oncology Diseases
        • 7.3.3.2. Chronic Diseases
        • 7.3.3.3. Autoimmune Diseases
        • 7.3.3.4. Blood Disorders
        • 7.3.3.5. Growth Hormone Deficiency
        • 7.3.3.6. Infectious Diseases
        • 7.3.3.7. Other Diseases
      • 7.3.4. Global Biosimilar Drug by: Form (Volume)
        • 7.3.4.1. Tablets
        • 7.3.4.2. Injection
        • 7.3.4.3. Others
      • 7.3.5. Global Biosimilar Drug Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Biosimilar Drug (Price)
      • 7.4.1. Global Biosimilar Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biosimilar Drug: by Type(USD Million)
  • Table 2. Biosimilar Drug Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others} , by Region USD Million (2016-2021)
  • Table 3. Biosimilar Drug Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Others} , by Region USD Million (2016-2021)
  • Table 4. Biosimilar Drug Recombinant Peptides {Glucagon, Calcitonin} , by Region USD Million (2016-2021)
  • Table 5. Biosimilar Drug: by Application(USD Million)
  • Table 6. Biosimilar Drug Cardiovascular , by Region USD Million (2016-2021)
  • Table 7. Biosimilar Drug Rheumatoid Arthrtis , by Region USD Million (2016-2021)
  • Table 8. Biosimilar Drug Tumor , by Region USD Million (2016-2021)
  • Table 9. Biosimilar Drug Ankylosing Spondylitis , by Region USD Million (2016-2021)
  • Table 10. Biosimilar Drug Others , by Region USD Million (2016-2021)
  • Table 11. Biosimilar Drug: by Disease(USD Million)
  • Table 12. Biosimilar Drug Oncology Diseases , by Region USD Million (2016-2021)
  • Table 13. Biosimilar Drug Chronic Diseases , by Region USD Million (2016-2021)
  • Table 14. Biosimilar Drug Autoimmune Diseases , by Region USD Million (2016-2021)
  • Table 15. Biosimilar Drug Blood Disorders , by Region USD Million (2016-2021)
  • Table 16. Biosimilar Drug Growth Hormone Deficiency , by Region USD Million (2016-2021)
  • Table 17. Biosimilar Drug Infectious Diseases , by Region USD Million (2016-2021)
  • Table 18. Biosimilar Drug Other Diseases , by Region USD Million (2016-2021)
  • Table 19. Biosimilar Drug: by Form(USD Million)
  • Table 20. Biosimilar Drug Tablets , by Region USD Million (2016-2021)
  • Table 21. Biosimilar Drug Injection , by Region USD Million (2016-2021)
  • Table 22. Biosimilar Drug Others , by Region USD Million (2016-2021)
  • Table 23. South America Biosimilar Drug, by Country USD Million (2016-2021)
  • Table 24. South America Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 25. South America Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 26. South America Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 27. South America Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 28. Brazil Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 29. Brazil Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 30. Brazil Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 31. Brazil Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 32. Argentina Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 33. Argentina Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 34. Argentina Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 35. Argentina Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 36. Rest of South America Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 37. Rest of South America Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 38. Rest of South America Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 39. Rest of South America Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 40. Asia Pacific Biosimilar Drug, by Country USD Million (2016-2021)
  • Table 41. Asia Pacific Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 42. Asia Pacific Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 43. Asia Pacific Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 44. Asia Pacific Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 45. China Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 46. China Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 47. China Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 48. China Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 49. Japan Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 50. Japan Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 51. Japan Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 52. Japan Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 53. India Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 54. India Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 55. India Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 56. India Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 57. South Korea Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 58. South Korea Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 59. South Korea Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 60. South Korea Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 61. Taiwan Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 62. Taiwan Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 63. Taiwan Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 64. Taiwan Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 65. Australia Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 66. Australia Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 67. Australia Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 68. Australia Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 70. Rest of Asia-Pacific Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 71. Rest of Asia-Pacific Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 72. Rest of Asia-Pacific Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 73. Europe Biosimilar Drug, by Country USD Million (2016-2021)
  • Table 74. Europe Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 75. Europe Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 76. Europe Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 77. Europe Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 78. Germany Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 79. Germany Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 80. Germany Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 81. Germany Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 82. France Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 83. France Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 84. France Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 85. France Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 86. Italy Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 87. Italy Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 88. Italy Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 89. Italy Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 90. United Kingdom Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 91. United Kingdom Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 92. United Kingdom Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 93. United Kingdom Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 94. Netherlands Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 95. Netherlands Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 96. Netherlands Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 97. Netherlands Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 98. Rest of Europe Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 99. Rest of Europe Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 100. Rest of Europe Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 101. Rest of Europe Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 102. MEA Biosimilar Drug, by Country USD Million (2016-2021)
  • Table 103. MEA Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 104. MEA Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 105. MEA Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 106. MEA Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 107. Middle East Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 108. Middle East Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 109. Middle East Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 110. Middle East Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 111. Africa Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 112. Africa Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 113. Africa Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 114. Africa Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 115. North America Biosimilar Drug, by Country USD Million (2016-2021)
  • Table 116. North America Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 117. North America Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 118. North America Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 119. North America Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 120. United States Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 121. United States Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 122. United States Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 123. United States Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 124. Canada Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 125. Canada Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 126. Canada Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 127. Canada Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 128. Mexico Biosimilar Drug, by Type USD Million (2016-2021)
  • Table 129. Mexico Biosimilar Drug, by Application USD Million (2016-2021)
  • Table 130. Mexico Biosimilar Drug, by Disease USD Million (2016-2021)
  • Table 131. Mexico Biosimilar Drug, by Form USD Million (2016-2021)
  • Table 132. Biosimilar Drug Sales: by Type(M Units)
  • Table 133. Biosimilar Drug Sales Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others} , by Region M Units (2016-2021)
  • Table 134. Biosimilar Drug Sales Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Others} , by Region M Units (2016-2021)
  • Table 135. Biosimilar Drug Sales Recombinant Peptides {Glucagon, Calcitonin} , by Region M Units (2016-2021)
  • Table 136. Biosimilar Drug Sales: by Application(M Units)
  • Table 137. Biosimilar Drug Sales Cardiovascular , by Region M Units (2016-2021)
  • Table 138. Biosimilar Drug Sales Rheumatoid Arthrtis , by Region M Units (2016-2021)
  • Table 139. Biosimilar Drug Sales Tumor , by Region M Units (2016-2021)
  • Table 140. Biosimilar Drug Sales Ankylosing Spondylitis , by Region M Units (2016-2021)
  • Table 141. Biosimilar Drug Sales Others , by Region M Units (2016-2021)
  • Table 142. Biosimilar Drug Sales: by Disease(M Units)
  • Table 143. Biosimilar Drug Sales Oncology Diseases , by Region M Units (2016-2021)
  • Table 144. Biosimilar Drug Sales Chronic Diseases , by Region M Units (2016-2021)
  • Table 145. Biosimilar Drug Sales Autoimmune Diseases , by Region M Units (2016-2021)
  • Table 146. Biosimilar Drug Sales Blood Disorders , by Region M Units (2016-2021)
  • Table 147. Biosimilar Drug Sales Growth Hormone Deficiency , by Region M Units (2016-2021)
  • Table 148. Biosimilar Drug Sales Infectious Diseases , by Region M Units (2016-2021)
  • Table 149. Biosimilar Drug Sales Other Diseases , by Region M Units (2016-2021)
  • Table 150. Biosimilar Drug Sales: by Form(M Units)
  • Table 151. Biosimilar Drug Sales Tablets , by Region M Units (2016-2021)
  • Table 152. Biosimilar Drug Sales Injection , by Region M Units (2016-2021)
  • Table 153. Biosimilar Drug Sales Others , by Region M Units (2016-2021)
  • Table 154. South America Biosimilar Drug Sales, by Country M Units (2016-2021)
  • Table 155. South America Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 156. South America Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 157. South America Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 158. South America Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 159. Brazil Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 160. Brazil Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 161. Brazil Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 162. Brazil Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 163. Argentina Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 164. Argentina Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 165. Argentina Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 166. Argentina Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 167. Rest of South America Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 168. Rest of South America Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 169. Rest of South America Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 170. Rest of South America Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 171. Asia Pacific Biosimilar Drug Sales, by Country M Units (2016-2021)
  • Table 172. Asia Pacific Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 173. Asia Pacific Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 174. Asia Pacific Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 175. Asia Pacific Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 176. China Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 177. China Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 178. China Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 179. China Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 180. Japan Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 181. Japan Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 182. Japan Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 183. Japan Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 184. India Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 185. India Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 186. India Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 187. India Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 188. South Korea Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 189. South Korea Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 190. South Korea Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 191. South Korea Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 192. Taiwan Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 193. Taiwan Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 194. Taiwan Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 195. Taiwan Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 196. Australia Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 197. Australia Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 198. Australia Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 199. Australia Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 200. Rest of Asia-Pacific Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 201. Rest of Asia-Pacific Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 202. Rest of Asia-Pacific Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 203. Rest of Asia-Pacific Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 204. Europe Biosimilar Drug Sales, by Country M Units (2016-2021)
  • Table 205. Europe Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 206. Europe Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 207. Europe Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 208. Europe Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 209. Germany Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 210. Germany Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 211. Germany Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 212. Germany Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 213. France Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 214. France Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 215. France Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 216. France Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 217. Italy Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 218. Italy Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 219. Italy Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 220. Italy Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 221. United Kingdom Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 222. United Kingdom Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 223. United Kingdom Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 224. United Kingdom Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 225. Netherlands Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 226. Netherlands Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 227. Netherlands Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 228. Netherlands Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 229. Rest of Europe Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 230. Rest of Europe Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 231. Rest of Europe Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 232. Rest of Europe Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 233. MEA Biosimilar Drug Sales, by Country M Units (2016-2021)
  • Table 234. MEA Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 235. MEA Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 236. MEA Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 237. MEA Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 238. Middle East Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 239. Middle East Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 240. Middle East Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 241. Middle East Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 242. Africa Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 243. Africa Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 244. Africa Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 245. Africa Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 246. North America Biosimilar Drug Sales, by Country M Units (2016-2021)
  • Table 247. North America Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 248. North America Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 249. North America Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 250. North America Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 251. United States Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 252. United States Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 253. United States Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 254. United States Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 255. Canada Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 256. Canada Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 257. Canada Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 258. Canada Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 259. Mexico Biosimilar Drug Sales, by Type M Units (2016-2021)
  • Table 260. Mexico Biosimilar Drug Sales, by Application M Units (2016-2021)
  • Table 261. Mexico Biosimilar Drug Sales, by Disease M Units (2016-2021)
  • Table 262. Mexico Biosimilar Drug Sales, by Form M Units (2016-2021)
  • Table 263. Biosimilar Drug: by Type(USD/Units)
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Company Basic Information, Sales Area and Its Competitors
  • Table 273. Company Basic Information, Sales Area and Its Competitors
  • Table 274. Biosimilar Drug: by Type(USD Million)
  • Table 275. Biosimilar Drug Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others} , by Region USD Million (2022-2027)
  • Table 276. Biosimilar Drug Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Others} , by Region USD Million (2022-2027)
  • Table 277. Biosimilar Drug Recombinant Peptides {Glucagon, Calcitonin} , by Region USD Million (2022-2027)
  • Table 278. Biosimilar Drug: by Application(USD Million)
  • Table 279. Biosimilar Drug Cardiovascular , by Region USD Million (2022-2027)
  • Table 280. Biosimilar Drug Rheumatoid Arthrtis , by Region USD Million (2022-2027)
  • Table 281. Biosimilar Drug Tumor , by Region USD Million (2022-2027)
  • Table 282. Biosimilar Drug Ankylosing Spondylitis , by Region USD Million (2022-2027)
  • Table 283. Biosimilar Drug Others , by Region USD Million (2022-2027)
  • Table 284. Biosimilar Drug: by Disease(USD Million)
  • Table 285. Biosimilar Drug Oncology Diseases , by Region USD Million (2022-2027)
  • Table 286. Biosimilar Drug Chronic Diseases , by Region USD Million (2022-2027)
  • Table 287. Biosimilar Drug Autoimmune Diseases , by Region USD Million (2022-2027)
  • Table 288. Biosimilar Drug Blood Disorders , by Region USD Million (2022-2027)
  • Table 289. Biosimilar Drug Growth Hormone Deficiency , by Region USD Million (2022-2027)
  • Table 290. Biosimilar Drug Infectious Diseases , by Region USD Million (2022-2027)
  • Table 291. Biosimilar Drug Other Diseases , by Region USD Million (2022-2027)
  • Table 292. Biosimilar Drug: by Form(USD Million)
  • Table 293. Biosimilar Drug Tablets , by Region USD Million (2022-2027)
  • Table 294. Biosimilar Drug Injection , by Region USD Million (2022-2027)
  • Table 295. Biosimilar Drug Others , by Region USD Million (2022-2027)
  • Table 296. South America Biosimilar Drug, by Country USD Million (2022-2027)
  • Table 297. South America Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 298. South America Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 299. South America Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 300. South America Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 301. Brazil Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 302. Brazil Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 303. Brazil Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 304. Brazil Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 305. Argentina Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 306. Argentina Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 307. Argentina Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 308. Argentina Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 309. Rest of South America Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 310. Rest of South America Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 311. Rest of South America Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 312. Rest of South America Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 313. Asia Pacific Biosimilar Drug, by Country USD Million (2022-2027)
  • Table 314. Asia Pacific Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 315. Asia Pacific Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 316. Asia Pacific Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 317. Asia Pacific Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 318. China Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 319. China Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 320. China Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 321. China Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 322. Japan Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 323. Japan Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 324. Japan Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 325. Japan Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 326. India Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 327. India Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 328. India Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 329. India Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 330. South Korea Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 331. South Korea Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 332. South Korea Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 333. South Korea Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 334. Taiwan Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 335. Taiwan Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 336. Taiwan Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 337. Taiwan Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 338. Australia Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 339. Australia Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 340. Australia Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 341. Australia Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 342. Rest of Asia-Pacific Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 343. Rest of Asia-Pacific Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 344. Rest of Asia-Pacific Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 345. Rest of Asia-Pacific Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 346. Europe Biosimilar Drug, by Country USD Million (2022-2027)
  • Table 347. Europe Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 348. Europe Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 349. Europe Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 350. Europe Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 351. Germany Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 352. Germany Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 353. Germany Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 354. Germany Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 355. France Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 356. France Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 357. France Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 358. France Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 359. Italy Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 360. Italy Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 361. Italy Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 362. Italy Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 363. United Kingdom Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 364. United Kingdom Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 365. United Kingdom Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 366. United Kingdom Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 367. Netherlands Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 368. Netherlands Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 369. Netherlands Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 370. Netherlands Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 371. Rest of Europe Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 372. Rest of Europe Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 373. Rest of Europe Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 374. Rest of Europe Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 375. MEA Biosimilar Drug, by Country USD Million (2022-2027)
  • Table 376. MEA Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 377. MEA Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 378. MEA Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 379. MEA Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 380. Middle East Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 381. Middle East Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 382. Middle East Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 383. Middle East Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 384. Africa Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 385. Africa Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 386. Africa Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 387. Africa Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 388. North America Biosimilar Drug, by Country USD Million (2022-2027)
  • Table 389. North America Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 390. North America Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 391. North America Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 392. North America Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 393. United States Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 394. United States Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 395. United States Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 396. United States Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 397. Canada Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 398. Canada Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 399. Canada Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 400. Canada Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 401. Mexico Biosimilar Drug, by Type USD Million (2022-2027)
  • Table 402. Mexico Biosimilar Drug, by Application USD Million (2022-2027)
  • Table 403. Mexico Biosimilar Drug, by Disease USD Million (2022-2027)
  • Table 404. Mexico Biosimilar Drug, by Form USD Million (2022-2027)
  • Table 405. Biosimilar Drug Sales: by Type(M Units)
  • Table 406. Biosimilar Drug Sales Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone, Insulin, Others} , by Region M Units (2022-2027)
  • Table 407. Biosimilar Drug Sales Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Others} , by Region M Units (2022-2027)
  • Table 408. Biosimilar Drug Sales Recombinant Peptides {Glucagon, Calcitonin} , by Region M Units (2022-2027)
  • Table 409. Biosimilar Drug Sales: by Application(M Units)
  • Table 410. Biosimilar Drug Sales Cardiovascular , by Region M Units (2022-2027)
  • Table 411. Biosimilar Drug Sales Rheumatoid Arthrtis , by Region M Units (2022-2027)
  • Table 412. Biosimilar Drug Sales Tumor , by Region M Units (2022-2027)
  • Table 413. Biosimilar Drug Sales Ankylosing Spondylitis , by Region M Units (2022-2027)
  • Table 414. Biosimilar Drug Sales Others , by Region M Units (2022-2027)
  • Table 415. Biosimilar Drug Sales: by Disease(M Units)
  • Table 416. Biosimilar Drug Sales Oncology Diseases , by Region M Units (2022-2027)
  • Table 417. Biosimilar Drug Sales Chronic Diseases , by Region M Units (2022-2027)
  • Table 418. Biosimilar Drug Sales Autoimmune Diseases , by Region M Units (2022-2027)
  • Table 419. Biosimilar Drug Sales Blood Disorders , by Region M Units (2022-2027)
  • Table 420. Biosimilar Drug Sales Growth Hormone Deficiency , by Region M Units (2022-2027)
  • Table 421. Biosimilar Drug Sales Infectious Diseases , by Region M Units (2022-2027)
  • Table 422. Biosimilar Drug Sales Other Diseases , by Region M Units (2022-2027)
  • Table 423. Biosimilar Drug Sales: by Form(M Units)
  • Table 424. Biosimilar Drug Sales Tablets , by Region M Units (2022-2027)
  • Table 425. Biosimilar Drug Sales Injection , by Region M Units (2022-2027)
  • Table 426. Biosimilar Drug Sales Others , by Region M Units (2022-2027)
  • Table 427. South America Biosimilar Drug Sales, by Country M Units (2022-2027)
  • Table 428. South America Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 429. South America Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 430. South America Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 431. South America Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 432. Brazil Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 433. Brazil Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 434. Brazil Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 435. Brazil Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 436. Argentina Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 437. Argentina Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 438. Argentina Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 439. Argentina Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 440. Rest of South America Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 441. Rest of South America Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 442. Rest of South America Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 443. Rest of South America Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 444. Asia Pacific Biosimilar Drug Sales, by Country M Units (2022-2027)
  • Table 445. Asia Pacific Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 446. Asia Pacific Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 447. Asia Pacific Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 448. Asia Pacific Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 449. China Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 450. China Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 451. China Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 452. China Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 453. Japan Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 454. Japan Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 455. Japan Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 456. Japan Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 457. India Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 458. India Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 459. India Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 460. India Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 461. South Korea Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 462. South Korea Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 463. South Korea Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 464. South Korea Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 465. Taiwan Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 466. Taiwan Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 467. Taiwan Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 468. Taiwan Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 469. Australia Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 470. Australia Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 471. Australia Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 472. Australia Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 473. Rest of Asia-Pacific Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 474. Rest of Asia-Pacific Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 475. Rest of Asia-Pacific Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 476. Rest of Asia-Pacific Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 477. Europe Biosimilar Drug Sales, by Country M Units (2022-2027)
  • Table 478. Europe Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 479. Europe Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 480. Europe Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 481. Europe Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 482. Germany Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 483. Germany Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 484. Germany Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 485. Germany Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 486. France Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 487. France Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 488. France Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 489. France Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 490. Italy Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 491. Italy Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 492. Italy Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 493. Italy Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 494. United Kingdom Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 495. United Kingdom Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 496. United Kingdom Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 497. United Kingdom Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 498. Netherlands Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 499. Netherlands Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 500. Netherlands Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 501. Netherlands Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 502. Rest of Europe Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 503. Rest of Europe Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 504. Rest of Europe Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 505. Rest of Europe Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 506. MEA Biosimilar Drug Sales, by Country M Units (2022-2027)
  • Table 507. MEA Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 508. MEA Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 509. MEA Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 510. MEA Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 511. Middle East Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 512. Middle East Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 513. Middle East Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 514. Middle East Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 515. Africa Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 516. Africa Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 517. Africa Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 518. Africa Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 519. North America Biosimilar Drug Sales, by Country M Units (2022-2027)
  • Table 520. North America Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 521. North America Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 522. North America Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 523. North America Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 524. United States Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 525. United States Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 526. United States Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 527. United States Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 528. Canada Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 529. Canada Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 530. Canada Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 531. Canada Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 532. Mexico Biosimilar Drug Sales, by Type M Units (2022-2027)
  • Table 533. Mexico Biosimilar Drug Sales, by Application M Units (2022-2027)
  • Table 534. Mexico Biosimilar Drug Sales, by Disease M Units (2022-2027)
  • Table 535. Mexico Biosimilar Drug Sales, by Form M Units (2022-2027)
  • Table 536. Biosimilar Drug: by Type(USD/Units)
  • Table 537. Research Programs/Design for This Report
  • Table 538. Key Data Information from Secondary Sources
  • Table 539. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biosimilar Drug: by Type USD Million (2016-2021)
  • Figure 5. Global Biosimilar Drug: by Application USD Million (2016-2021)
  • Figure 6. Global Biosimilar Drug: by Disease USD Million (2016-2021)
  • Figure 7. Global Biosimilar Drug: by Form USD Million (2016-2021)
  • Figure 8. South America Biosimilar Drug Share (%), by Country
  • Figure 9. Asia Pacific Biosimilar Drug Share (%), by Country
  • Figure 10. Europe Biosimilar Drug Share (%), by Country
  • Figure 11. MEA Biosimilar Drug Share (%), by Country
  • Figure 12. North America Biosimilar Drug Share (%), by Country
  • Figure 13. Global Biosimilar Drug: by Type M Units (2016-2021)
  • Figure 14. Global Biosimilar Drug: by Application M Units (2016-2021)
  • Figure 15. Global Biosimilar Drug: by Disease M Units (2016-2021)
  • Figure 16. Global Biosimilar Drug: by Form M Units (2016-2021)
  • Figure 17. South America Biosimilar Drug Share (%), by Country
  • Figure 18. Asia Pacific Biosimilar Drug Share (%), by Country
  • Figure 19. Europe Biosimilar Drug Share (%), by Country
  • Figure 20. MEA Biosimilar Drug Share (%), by Country
  • Figure 21. North America Biosimilar Drug Share (%), by Country
  • Figure 22. Global Biosimilar Drug: by Type USD/Units (2016-2021)
  • Figure 23. Global Biosimilar Drug share by Players 2021 (%)
  • Figure 24. Global Biosimilar Drug share by Players (Top 3) 2021(%)
  • Figure 25. Global Biosimilar Drug share by Players (Top 5) 2021(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer (United States) Revenue: by Geography 2021
  • Figure 29. Sandoz International (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Sandoz International (Germany) Revenue: by Geography 2021
  • Figure 31. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Teva Pharmaceuticals (Israel) Revenue: by Geography 2021
  • Figure 33. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 34. Amgen (United States) Revenue: by Geography 2021
  • Figure 35. Biocon (India) Revenue, Net Income and Gross profit
  • Figure 36. Biocon (India) Revenue: by Geography 2021
  • Figure 37. Dr. Reddy’s Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 38. Dr. Reddy’s Laboratories (India) Revenue: by Geography 2021
  • Figure 39. Celltrion (South Korea) Revenue, Net Income and Gross profit
  • Figure 40. Celltrion (South Korea) Revenue: by Geography 2021
  • Figure 41. Samsung Biologics (South Korea) Revenue, Net Income and Gross profit
  • Figure 42. Samsung Biologics (South Korea) Revenue: by Geography 2021
  • Figure 43. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 44. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 45. Henlius Biotech (China) Revenue, Net Income and Gross profit
  • Figure 46. Henlius Biotech (China) Revenue: by Geography 2021
  • Figure 47. Global Biosimilar Drug: by Type USD Million (2022-2027)
  • Figure 48. Global Biosimilar Drug: by Application USD Million (2022-2027)
  • Figure 49. Global Biosimilar Drug: by Disease USD Million (2022-2027)
  • Figure 50. Global Biosimilar Drug: by Form USD Million (2022-2027)
  • Figure 51. South America Biosimilar Drug Share (%), by Country
  • Figure 52. Asia Pacific Biosimilar Drug Share (%), by Country
  • Figure 53. Europe Biosimilar Drug Share (%), by Country
  • Figure 54. MEA Biosimilar Drug Share (%), by Country
  • Figure 55. North America Biosimilar Drug Share (%), by Country
  • Figure 56. Global Biosimilar Drug: by Type M Units (2022-2027)
  • Figure 57. Global Biosimilar Drug: by Application M Units (2022-2027)
  • Figure 58. Global Biosimilar Drug: by Disease M Units (2022-2027)
  • Figure 59. Global Biosimilar Drug: by Form M Units (2022-2027)
  • Figure 60. South America Biosimilar Drug Share (%), by Country
  • Figure 61. Asia Pacific Biosimilar Drug Share (%), by Country
  • Figure 62. Europe Biosimilar Drug Share (%), by Country
  • Figure 63. MEA Biosimilar Drug Share (%), by Country
  • Figure 64. North America Biosimilar Drug Share (%), by Country
  • Figure 65. Global Biosimilar Drug: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Sandoz International (Germany)
  • Teva Pharmaceuticals (Israel)
  • Amgen (United States)
  • Biocon (India)
  • Dr. Reddy’s Laboratories (India)
  • Celltrion (South Korea)
  • Samsung Biologics (South Korea)
  • Eli Lilly and Company (United States)
  • Henlius Biotech (China)
Additional players considered in the study are as follows:
CP Guojian (China) , Novartis International AG (Switzerland) , Amgen Inc. (United States) , Changchun High Tech (China) , Celgene Corporation (United States)
Select User Access Type

Key Highlights of Report


Oct 2019 212 Pages 57 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Biosimilar Drug Quantitative research analysis
Global Biosimilar Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Demand for Biosimilar Drugs Due to Their Cost-Effectiveness " is seen as one of major growth factors of Biosimilar Drug Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead Biosimilar Drug Market in coming years.

Know More About Global Biosimilar Drug Report?

Have a Query? Click Here

Other Related Reports

Sinusitis Drugs Comprehensive Study by Type (Analgesics, Antibiotics, Antihistamines, Corticosteroids, Decongestants, Sulphonamides), Application (Acute Sinusitis, Chronic Sinusitis), Treatment (Anti...
$ 3650
Barbiturate Drugs Comprehensive Study by Type (Phenobarbital, Amobarbital, Secobarbital, Pentobarbital, Others), Application (Insomnia, Seizures, Headaches, Others), Nature (Ultra-Short Acting Barbit...
$ 3750
Pigmented Villonodular Synovitis Drug Comprehensive Study by Type (Cabiralizumab, Emactuzumab, Mcs-110, Nilotinib, Others), Application (Reduces Swelling, Relieves Pain, Others), Distribution Channel...
$ 3650
Immunotherapy Drugs Comprehensive Study by Type (Monoclonal Antibodies, Adult Vaccines (Preventive Vaccines, Therapeutic Vaccines), Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins, Othe...
$ 3750
Allyl Methacrylate Comprehensive Study by Type (Allyl Methacrylate 98%, Allyl Methacrylate 99.5%), Application (Paints& Coatings, Floor Polishes, Dentistry Materials, Other), Distribution Channel (Di...
$ 3350
Cat Allergy Comprehensive Study by Type (Antihistamine, Decongestants Medication), Application (Hospital, Ambulatory Surgical Centers), Test Type (Scratch test, Intradermal test) Players and Region -...
$ 3500